Raffi Karagozian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Raffi Karagozian has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Dorothy B. Wakefield
4 shared publications- Gyorgy Baffy
Department of Medicine, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
2 shared publications Aakash Agarwal
1 shared publicationAnna E. Rutherford
Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA
1 shared publicationDaniela Guerrero Vinsard
1 shared publicationDorothy Wakefield
1 shared publication
Latest Publications
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
13 - Vaccine-Preventable Diseases in Hospitalized Patients with Inflammatory Bowel Disease: A Nationwide Cohort Analysis
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
13 - Vaccine-Preventable Diseases in Hospitalized Patients with Inflammatory Bowel Disease: A Nationwide Cohort Analysis
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
427 - Cirrhosis as a Risk Factor for Poor Outcomes and Surgical Complications in Patients with Orthopedic Fractures–An NIS Study
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
427 - Cirrhosis as a Risk Factor for Poor Outcomes and Surgical Complications in Patients with Orthopedic Fractures–An NIS Study
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1142
Sarcopenia is Signficantly Under Recognized in Hospitalized Patients with Cirrhosis
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1142
Sarcopenia is Signficantly Under Recognized in Hospitalized Patients with Cirrhosis
- 4 May 2016
- Published by Wiley in Liver International
- Vol. 36 (10) , 1450-1456
Obesity paradox in advanced liver disease: obesity is associated with lower mortality in hospitalized patients with cirrhosis
Background & Aims: To investigate how obesity impacts inpatient mortality, length of stay (LOS) and costs in patients with cirrhosis. Obesity is a growing epidemic associated with multiple co‐morbidities, increased morbidity, and a significant economic burden on healthcare. Despite the overall harmful impact of obesity, the ‘obesity paradox’ has been described as decreased mortality among obese vs non‐obese patients in various chronic medical conditions.Methods: Analysis of the Nationwide Inpatient Sample (NIS) for 2012, which contains data from 44 states and 4378 hospitals. Data from all cases with primary, secondary or tertiary discharge diagnosis of cirrhosis identified by International Classification of Diseases‐9 code 571.2, 571.5 571.6 were included. Primary outcomes included inpatient mortality, LOS, and hospital charges. Obesity as a predictor of mortality was defined by a predetermined obesity co‐morbidity variable.Results: A total of 32,605 patients were included. Crude mortality was lower for obese cirrhotic patients (2.7% vs 3.5%, P = 0.02) than for non‐obese cirrhotic patients. In contrast, median LOS was longer (4 vs 3 days, P < 0.001) and median hospital charges were higher for obese cirrhotic patients ($26 803 vs $23 447, P < 0.001) In multivariate logistic regression, obesity was associated with a lower risk of inpatient mortality (OR=0.73, 95%CI: 0.55–0.95, P = 0.02).Conclusions: In the acute care setting, obese patients with cirrhosis have lower mortality than non‐obese patients with cirrhosis, longer hospitalizations and higher healthcare cost, providing new evidence for the obesity paradox in cirrhosis. Obese cirrhotic patients are more likely to have enhanced nutritional reserve which may play a role in survival during acute illness.
- 4 May 2016
- Published by Wiley in Liver International
- Vol. 36 (10) , 1450-1456
Obesity paradox in advanced liver disease: obesity is associated with lower mortality in hospitalized patients with cirrhosis
Background & Aims: To investigate how obesity impacts inpatient mortality, length of stay (LOS) and costs in patients with cirrhosis. Obesity is a growing epidemic associated with multiple co‐morbidities, increased morbidity, and a significant economic burden on healthcare. Despite the overall harmful impact of obesity, the ‘obesity paradox’ has been described as decreased mortality among obese vs non‐obese patients in various chronic medical conditions.Methods: Analysis of the Nationwide Inpatient Sample (NIS) for 2012, which contains data from 44 states and 4378 hospitals. Data from all cases with primary, secondary or tertiary discharge diagnosis of cirrhosis identified by International Classification of Diseases‐9 code 571.2, 571.5 571.6 were included. Primary outcomes included inpatient mortality, LOS, and hospital charges. Obesity as a predictor of mortality was defined by a predetermined obesity co‐morbidity variable.Results: A total of 32,605 patients were included. Crude mortality was lower for obese cirrhotic patients (2.7% vs 3.5%, P = 0.02) than for non‐obese cirrhotic patients. In contrast, median LOS was longer (4 vs 3 days, P < 0.001) and median hospital charges were higher for obese cirrhotic patients ($26 803 vs $23 447, P < 0.001) In multivariate logistic regression, obesity was associated with a lower risk of inpatient mortality (OR=0.73, 95%CI: 0.55–0.95, P = 0.02).Conclusions: In the acute care setting, obese patients with cirrhosis have lower mortality than non‐obese patients with cirrhosis, longer hospitalizations and higher healthcare cost, providing new evidence for the obesity paradox in cirrhosis. Obese cirrhotic patients are more likely to have enhanced nutritional reserve which may play a role in survival during acute illness.
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S1024
283 Acute Kidney Injury Is Associated With Significantly Higher Healthcare Costs in Hospitalized Patients With Cirrhosis: National Inpatient Sample
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S1024
283 Acute Kidney Injury Is Associated With Significantly Higher Healthcare Costs in Hospitalized Patients With Cirrhosis: National Inpatient Sample
- 17 March 2016
- Published by Wiley in Clinical Transplantation
- Vol. 30 (5) , 502-507
Spontaneous bacterial peritonitis is a risk factor for renal failure requiring dialysis in waitlisted liver transplant candidates
Aims: To examine the relationship between and impact of spontaneous bacteria peritonitis (SBP) and renal failure requiring dialysis in waitlisted liver transplant (LT) candidates.Background: Renal failure is a common and severe complication in cirrhotic patients withSBP. Approximately one‐third of patients withSBPdevelop renal failure despite treatment of infection. However, the incidence of renal failure requiring dialysis inLTwaitlisted patients who have developedSBPis unknown. The high mortality observed in this group has also raised debate about resource utilization in the care of these patients.Methods: Data from the United Network for Organ Sharing Standard Transplant and Research files were collected retrospectively between 1994 and 2012. The primary endpoint measured was first time initiation of dialysis while on theLTwait list. Secondary endpoints included waitlist time and mortality on wait list.Results: A total of 42,085 patients were included.SBPat time of listing was diagnosed in 2,352 patients (5.6%) and first time initiation of dialysis while on the wait list occurred in 2,367 patients (6.2%). UnadjustedORfor requiring dialysis for patients listed withSBPwas 1.66 (p < 0.001). When controlled for age, gender,BMI, diabetes mellitus, baseline creatinine,MELDscore, serum albumin at listing, the adjustedORfor dialysis was 1.24 (p = 0.007) in waitlisted patients withSBP. Patients withSBPat time of listing had a mean waitlist time 142.1 d vs. 198.7 d in non‐SBPpatients (p < 0.001).Conclusions: Spontaneous bacteria peritonitis patients have a significantly increased likelihood to require dialysis and mean shorter waitlist time. Furthermore, the combined occurrence ofSBPand dialysis is a strong risk factor for all‐cause mortality while on theLTwait list.
- 17 March 2016
- Published by Wiley in Clinical Transplantation
- Vol. 30 (5) , 502-507
Spontaneous bacterial peritonitis is a risk factor for renal failure requiring dialysis in waitlisted liver transplant candidates
Aims: To examine the relationship between and impact of spontaneous bacteria peritonitis (SBP) and renal failure requiring dialysis in waitlisted liver transplant (LT) candidates.Background: Renal failure is a common and severe complication in cirrhotic patients withSBP. Approximately one‐third of patients withSBPdevelop renal failure despite treatment of infection. However, the incidence of renal failure requiring dialysis inLTwaitlisted patients who have developedSBPis unknown. The high mortality observed in this group has also raised debate about resource utilization in the care of these patients.Methods: Data from the United Network for Organ Sharing Standard Transplant and Research files were collected retrospectively between 1994 and 2012. The primary endpoint measured was first time initiation of dialysis while on theLTwait list. Secondary endpoints included waitlist time and mortality on wait list.Results: A total of 42,085 patients were included.SBPat time of listing was diagnosed in 2,352 patients (5.6%) and first time initiation of dialysis while on the wait list occurred in 2,367 patients (6.2%). UnadjustedORfor requiring dialysis for patients listed withSBPwas 1.66 (p < 0.001). When controlled for age, gender,BMI, diabetes mellitus, baseline creatinine,MELDscore, serum albumin at listing, the adjustedORfor dialysis was 1.24 (p = 0.007) in waitlisted patients withSBP. Patients withSBPat time of listing had a mean waitlist time 142.1 d vs. 198.7 d in non‐SBPpatients (p < 0.001).Conclusions: Spontaneous bacteria peritonitis patients have a significantly increased likelihood to require dialysis and mean shorter waitlist time. Furthermore, the combined occurrence ofSBPand dialysis is a strong risk factor for all‐cause mortality while on theLTwait list.
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Su2046 Hepatocellular Carcinoma Among US Veterans: Recent Trends and Implications
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Su2046 Hepatocellular Carcinoma Among US Veterans: Recent Trends and Implications